Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study.
CellSearch® system
EPISPOT assay
circulating tumor cells
colorectal cancer
predictive value
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Jun 2021
13 Jun 2021
Historique:
received:
21
05
2021
revised:
09
06
2021
accepted:
10
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Circulating tumor cells (CTCs) allow the real-time monitoring of tumor course and treatment response. This prospective multicenter study evaluates and compares the early predictive value of CTC enumeration with EPISPOT, a functional assay that detects only viable CTCs, and with the CellSearch Treatment-naive patients with mCRC and measurable disease (RECIST criteria 1.1) received FOLFIRI-bevacizumab until progression or unacceptable toxicity. CTCs in peripheral blood were enumerated at D With the EPISPOT assay, at least 1 viable CTC was detected in 21% (D CTC detection at D
Sections du résumé
BACKGROUND
BACKGROUND
Circulating tumor cells (CTCs) allow the real-time monitoring of tumor course and treatment response. This prospective multicenter study evaluates and compares the early predictive value of CTC enumeration with EPISPOT, a functional assay that detects only viable CTCs, and with the CellSearch
METHODS
METHODS
Treatment-naive patients with mCRC and measurable disease (RECIST criteria 1.1) received FOLFIRI-bevacizumab until progression or unacceptable toxicity. CTCs in peripheral blood were enumerated at D
RESULTS
RESULTS
With the EPISPOT assay, at least 1 viable CTC was detected in 21% (D
CONCLUSIONS
CONCLUSIONS
CTC detection at D
Identifiants
pubmed: 34199250
pii: cancers13122966
doi: 10.3390/cancers13122966
pmc: PMC8231886
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Institut National Du Cancer
ID : 2011-049
Organisme : SIRIC Montpellier Cancer
ID : INCa_Inserm_DGOS_12553
Références
Oncologist. 2012;17(7):947-55
pubmed: 22643538
J Oncol. 2011;2011:252361
pubmed: 21577258
Clin Chem. 2013 Sep;59(9):1384-92
pubmed: 23695297
Dig Liver Dis. 2019 Oct;51(10):1357-1363
pubmed: 31320305
Clin Med Insights Oncol. 2016 Apr 27;10(Suppl 1):41-55
pubmed: 27147901
Cells. 2019 Jul 20;8(7):
pubmed: 31330795
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Sci Rep. 2016 Dec 21;6:39736
pubmed: 28000772
Front Oncol. 2019 Dec 13;9:1427
pubmed: 31921680
J Clin Oncol. 2008 Jul 1;26(19):3213-21
pubmed: 18591556
Lancet Oncol. 2014 Apr;15(4):406-14
pubmed: 24636208
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
N Engl J Med. 2004 Aug 19;351(8):781-91
pubmed: 15317891
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Onco Targets Ther. 2016 Dec 13;9:7503-7513
pubmed: 28008271
Oncotarget. 2014 Sep 15;5(17):7486-97
pubmed: 25277187
JAMA Oncol. 2021 Jan 1;7(1):34-41
pubmed: 33151266
Clin Cancer Res. 2007 Feb 1;13(3):920-8
pubmed: 17289886
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
J Natl Compr Canc Netw. 2021 Mar 02;19(3):329-359
pubmed: 33724754
Cancer Biol Ther. 2015;16(5):690-8
pubmed: 25785486
Lancet Oncol. 2015 Oct;16(13):1306-15
pubmed: 26338525
Clin Colorectal Cancer. 2015 Jun;14(2):115-22.e1-2
pubmed: 25680623
Ann Oncol. 2010 May;21(5):1006-12
pubmed: 19861577
Clin Chem. 2014 Jan;60(1):214-21
pubmed: 24255082
Clin Colorectal Cancer. 2020 Sep;19(3):e110-e116
pubmed: 32278676
Methods Mol Biol. 2017;1634:263-276
pubmed: 28819858
Br J Cancer. 2009 Aug 18;101(4):715-21
pubmed: 19603018
N Engl J Med. 2013 Sep 12;369(11):1023-34
pubmed: 24024839
Clin Chem. 2019 Oct;65(10):1267-1275
pubmed: 31387885
Trends Mol Med. 2010 Sep;16(9):398-406
pubmed: 20667783